FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023493856> ?p ?o ?g. }

• W2023493856 endingPage "1913" @default.
• W2023493856 startingPage "1907" @default.
• W2023493856 abstract "BackgroundThis study investigates the protective effect of exogenous αB-crystallin (CryAB) on myocardial function after ischemia-reperfusion injury.MethodsMice underwent temporary left anterior descending artery occlusion for 30 minutes. Either CryAB (50 μg) or phosphate-buffered saline (100 μL [n = 6, each group]) were injected in the intramyocardial medial and lateral perinfarct zone 15 minutes before reperfusion. Intraperitoneal injections were administered every other day. Left ventricular ejection fraction was evaluated on postoperative day 40 with magnetic resonance imaging. To investigate the effect of CryAB on apoptosis after hypoxia/reoxygenation in vitro, murine atrial cardiomyocytes (HL-1 cells) or human microvascular endothelial cells (HMEC-1) were incubated with either 50 μg CryAB (500 μg /10 mL) or phosphate-buffered saline in a hypoxia chamber for 6, 12, and 24 hours, followed by 30 minutes of reoxygenation at room air. Apoptosis was then assessed by western blot (Bcl-2, free bax, cleaved caspases-3, 9, PARP) and enzyme-linked immunosorbent assay analyses (cytoplasmic histone-associated DNA fragments and caspase-3 activity).ResultsOn postoperative day 40, CryAB-treated mice had a 1.8-fold increase in left ventricular ejection fraction versus control mice (27% ± 6% versus 15% ± 4% SD, p < 0.005). In vitro, (1) the HL-1 cells showed no significant difference in apoptotic protein expression, cytoplasmic histone-associated DNA fragments, or caspase-3 activity; (2) the HMEC-1 cells had increased but not significant apoptotic protein expression with, however, a significant decrease in cytoplasmic histone-associated DNA fragments (1.5-fold, p < 0.01) and caspase-3 activity (2.7-fold, p < 0.005).ConclusionsExogenous CryAB administration significantly improves cardiac function after ischemia-reperfusion injury, in vivo. The protective anti-apoptotic affects of CryAB may target the endothelial cell. This study investigates the protective effect of exogenous αB-crystallin (CryAB) on myocardial function after ischemia-reperfusion injury. Mice underwent temporary left anterior descending artery occlusion for 30 minutes. Either CryAB (50 μg) or phosphate-buffered saline (100 μL [n = 6, each group]) were injected in the intramyocardial medial and lateral perinfarct zone 15 minutes before reperfusion. Intraperitoneal injections were administered every other day. Left ventricular ejection fraction was evaluated on postoperative day 40 with magnetic resonance imaging. To investigate the effect of CryAB on apoptosis after hypoxia/reoxygenation in vitro, murine atrial cardiomyocytes (HL-1 cells) or human microvascular endothelial cells (HMEC-1) were incubated with either 50 μg CryAB (500 μg /10 mL) or phosphate-buffered saline in a hypoxia chamber for 6, 12, and 24 hours, followed by 30 minutes of reoxygenation at room air. Apoptosis was then assessed by western blot (Bcl-2, free bax, cleaved caspases-3, 9, PARP) and enzyme-linked immunosorbent assay analyses (cytoplasmic histone-associated DNA fragments and caspase-3 activity). On postoperative day 40, CryAB-treated mice had a 1.8-fold increase in left ventricular ejection fraction versus control mice (27% ± 6% versus 15% ± 4% SD, p < 0.005). In vitro, (1) the HL-1 cells showed no significant difference in apoptotic protein expression, cytoplasmic histone-associated DNA fragments, or caspase-3 activity; (2) the HMEC-1 cells had increased but not significant apoptotic protein expression with, however, a significant decrease in cytoplasmic histone-associated DNA fragments (1.5-fold, p < 0.01) and caspase-3 activity (2.7-fold, p < 0.005). Exogenous CryAB administration significantly improves cardiac function after ischemia-reperfusion injury, in vivo. The protective anti-apoptotic affects of CryAB may target the endothelial cell." @default.
• W2023493856 created "2016-06-24" @default.
• W2023493856 creator A5002094342 @default.
• W2023493856 creator A5008505299 @default.
• W2023493856 creator A5011144095 @default.
• W2023493856 creator A5018679794 @default.
• W2023493856 creator A5021775232 @default.
• W2023493856 creator A5039422327 @default.
• W2023493856 creator A5054247350 @default.
• W2023493856 creator A5057854812 @default.
• W2023493856 creator A5062163412 @default.
• W2023493856 creator A5090049313 @default.
• W2023493856 date "2011-06-01" @default.
• W2023493856 modified "2023-10-12" @default.
• W2023493856 title "αB-Crystallin Improves Murine Cardiac Function and Attenuates Apoptosis in Human Endothelial Cells Exposed to Ischemia-Reperfusion" @default.
• W2023493856 cites W1493231819 @default.
• W2023493856 cites W1965286369 @default.
• W2023493856 cites W1967269091 @default.
• W2023493856 cites W1967368426 @default.
• W2023493856 cites W1971122033 @default.
• W2023493856 cites W1988580831 @default.
• W2023493856 cites W1990652761 @default.
• W2023493856 cites W1994446230 @default.
• W2023493856 cites W2000828075 @default.
• W2023493856 cites W2004767190 @default.
• W2023493856 cites W2019175855 @default.
• W2023493856 cites W2019270143 @default.
• W2023493856 cites W2023035256 @default.
• W2023493856 cites W2032705499 @default.
• W2023493856 cites W2034825883 @default.
• W2023493856 cites W2047579358 @default.
• W2023493856 cites W2080713537 @default.
• W2023493856 cites W2103245988 @default.
• W2023493856 cites W2107886181 @default.
• W2023493856 cites W2108866575 @default.
• W2023493856 cites W2109846452 @default.
• W2023493856 cites W2111486034 @default.
• W2023493856 cites W2114792019 @default.
• W2023493856 cites W2118585536 @default.
• W2023493856 cites W2121238553 @default.
• W2023493856 cites W2137582720 @default.
• W2023493856 cites W2151722542 @default.
• W2023493856 cites W2154388708 @default.
• W2023493856 cites W2172159030 @default.
• W2023493856 cites W2337833709 @default.
• W2023493856 doi "https://doi.org/10.1016/j.athoracsur.2011.02.072" @default.
• W2023493856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21619989" @default.
• W2023493856 hasPublicationYear "2011" @default.
• W2023493856 type Work @default.
• W2023493856 sameAs 2023493856 @default.
• W2023493856 citedByCount "59" @default.
• W2023493856 countsByYear W20234938562012 @default.
• W2023493856 countsByYear W20234938562013 @default.
• W2023493856 countsByYear W20234938562014 @default.
• W2023493856 countsByYear W20234938562015 @default.
• W2023493856 countsByYear W20234938562016 @default.
• W2023493856 countsByYear W20234938562017 @default.
• W2023493856 countsByYear W20234938562018 @default.
• W2023493856 countsByYear W20234938562019 @default.
• W2023493856 countsByYear W20234938562020 @default.
• W2023493856 countsByYear W20234938562021 @default.
• W2023493856 countsByYear W20234938562023 @default.
• W2023493856 crossrefType "journal-article" @default.
• W2023493856 hasAuthorship W2023493856A5002094342 @default.
• W2023493856 hasAuthorship W2023493856A5008505299 @default.
• W2023493856 hasAuthorship W2023493856A5011144095 @default.
• W2023493856 hasAuthorship W2023493856A5018679794 @default.
• W2023493856 hasAuthorship W2023493856A5021775232 @default.
• W2023493856 hasAuthorship W2023493856A5039422327 @default.
• W2023493856 hasAuthorship W2023493856A5054247350 @default.
• W2023493856 hasAuthorship W2023493856A5057854812 @default.
• W2023493856 hasAuthorship W2023493856A5062163412 @default.
• W2023493856 hasAuthorship W2023493856A5090049313 @default.
• W2023493856 hasBestOaLocation W20234938561 @default.
• W2023493856 hasConcept C104317684 @default.
• W2023493856 hasConcept C12519072 @default.
• W2023493856 hasConcept C126322002 @default.
• W2023493856 hasConcept C153911025 @default.
• W2023493856 hasConcept C16685009 @default.
• W2023493856 hasConcept C178790620 @default.
• W2023493856 hasConcept C185592680 @default.
• W2023493856 hasConcept C190283241 @default.
• W2023493856 hasConcept C202751555 @default.
• W2023493856 hasConcept C2776415932 @default.
• W2023493856 hasConcept C2778198053 @default.
• W2023493856 hasConcept C2780114680 @default.
• W2023493856 hasConcept C31573885 @default.
• W2023493856 hasConcept C540031477 @default.
• W2023493856 hasConcept C541997718 @default.
• W2023493856 hasConcept C552990157 @default.
• W2023493856 hasConcept C55493867 @default.
• W2023493856 hasConcept C64927066 @default.
• W2023493856 hasConcept C71924100 @default.
• W2023493856 hasConcept C78085059 @default.
• W2023493856 hasConcept C7836513 @default.
• W2023493856 hasConcept C86803240 @default.
• W2023493856 hasConceptScore W2023493856C104317684 @default.
• W2023493856 hasConceptScore W2023493856C12519072 @default.

• next